版权说明：本文档由用户提供并上传，收益归属内容提供方，若内容存在侵权，请进行举报或认领
文档简介
ManagementofunresectablestageⅢnon-smallcelllungcancer:theroleofcombinedchemoradiationManagementofunresectablesta1introduction
Untilthelate1980s,thoracicradiationtherapy(TRT)remainedthestandardcareforlocallyadvancedNSCLC.introductionUntilthelate12Radiationalone?Sequentialchemoradiation?Radiationalone?Sequentialch3CALGB8433RT60GyPV2cycles＋RT60GyNo.7779MST9.713.81-yearsurvival40552yearsurvival13263yearsurvival11235yearsurvival719Pvalue0.0066DillmanRO,NEJM323:940-945,1990DillmanRO,JNCI88:1210-1215,1996CALGB8433RT60GyPV2cycles＋RT60G4RTOG8808RT60GyCT+RTH-RT69.6GyNo152152154MST11.413.2121-yearsurvival4759522-yearsurvival2132243-yearsurvival1117145-yearsurvival6119Pvalue
0.04SauseW,JNCI1995;87:198-205SauseW,CHEST2000;117:358-364RTOG8808RT60GyCT+RTH-RT69.6GyN5OSOS6<60ysurvival<60ysurvival7FRANCERT65GyCT+RT65GyP值No177176MST10120.081-yearsurvival41502-yearsurvival14213-yearsurvival511Metastasisrate3826<0.0011-yearLCR1715ThierryLeChevaliar,JNCI1991;83:417-423CT:VCPC,vindesine,cyclophosphamide,cisplatin,lomustineFRANCERT65GyCT+RT65GyP值No177178Concurrentchemoradiation?Radiationalone?Concurrentchemoradiation?Radi9EORTCRT55PDD(W)+RTPDD(D)+RTNo3113113111-ysurvival4644542-ysurvival1319263-ysurvival21316Pvalue0.0091-yLCR193031Pvalue0.003Schaake-KoningC,NEJM1992;326:524-530EORTCRT55PDD(W)+RTPDD(D)+RTNo310IntensifiedregimenH-RTH-RT/CTH-RT/CTNo615256methods64.8Gy64.8/CE64.8/CEMST818133-ysurvival6.62316JeremicB,JCO1995;13:452-458LeeJS,JCO1994;14:1055-1064CT:weekly,100mg/m2CBPD1,D2;100mg/m2VP-16D1-3CT:200mg/m2CBPD1,D2;100mg/m2VP-16D1-5,thefirst,third,andfifthweeks
IntensifiedregimenH-RTH-RT/CT11MetaAnalysisResults(52trials,9387pts)
2-yearsurvival4%。
Hazard
ratio:0.87。NSCLCCG,BMJ1995;311:899-909MetaAnalysisResults(52trial12Concurrentchemoradiation?Sequentialchemoradiation?Concurrentchemoradiation?Sequ13concurrentsequentialPvalueNo156158methods56Gy/MVP2CMVP2C+56MST16.513.30.042-ysurvival34.627.43-ysurvival22.314.74-ysurvival16.910.15-ysurvival15.88.9ResponseR84660.0002FuruseK,JCO1999;17:2692-2699JapanconcurrentsequentialPvalueNo114RTOG9410sequentialconcurrentconcurrent+HFNo(total)611RT606069.6methodsPV2CPV2CPEMST14.61715.6A-Toxicity304862L-Toxicity141516CurranWJ,PASCO2000;19:484aRTOG9410sequentialconcurrentco15ACR427(phaseⅡ)seqCon(ind/con)Con(con/adi)No(total)276RT636363CTPC2PC2+CONCON+PC2MST12.51116.1Esophogitis(≥3）42028ChoyH,PASCO2002;abstract:1160ACR427(phaseⅡ)seqCon(ind/con)16GLOT9501SEQCONNo(total)212RT66Gy66CTNP3CindCE+CE2Cadi3/4neutropenia
87.8753/4oesophagitis026.1MST13.915.61-ysurvival56562-ysurvival2335PierreF,PASCO2001;abstract:1246GLOT9501SEQCONNo(total)212RT6617MSTOSE-toxicity
S
C
SCSCfuruse13.3
16.5
916(5)423RTOG14.617.1
1221(4)
425GLOT13.915.6
2435(2)317Czech13.220.6
1542(2)428BROCAT14.019.0
--026ACR42713.817.4
3133(2)328MSTOSE-toxicityS18CALGB9431G/PP/PN/PNo.625855RR7467731-ySur6862653-ySur281923MST18.314.817.7DFSMethods:2cyclesinductionfollowedby2cyclesandconcurrentTRT,66GyVokesEE,JCO2002;20:4191-4198CALGB9431G/PP/PN/PNo.625855RR719CALGB9431CALGB943120SWOG9019Patients:
50pts.IIIB
Treatment:PE2cycles/RTPE2cyclesAlbainKS,JCO2002;20:3454-3460SWOG9019Patients:50pts.IIIB21SWOG9019MST:15months1y-sur:58%2y-sur:33%3y-sur:17%5y-sur:15%SWOG9019MST:15months1y-sur:522SWOG9504Patients:
83pts.IIIB
Treatment:PE2cycles/RTDocetaxel3cycles(75mg/m2forthefirstand100mg/m2forthelasttwocycles).GandaraDR,JCO2003;21:2004-2010SWOG9504Patients:83pts.IIIB23SWOG95041y-sur:76%MST:26months2y-sur:54%3y-sur:37%SWOG95041y-sur:76%MST:26mont24SWOG9019/9504studyNoSurvivaltime2y-Survival3y-survivalmedian95%CImedian95%CImedian95%CI9019501510-223421-47177-279504832618-355443-653722-52GandaraDR,JCO2003;21:2004-2010SWOG9019/9504studyNoSurvivalt25HossierOncologyGroupInductioncisplatin/etoposideTRTDocetaxelObservationHossierOncologyGroupInductio26CALGB9801InductionPCNoInductionPCconcurrentcarboplatin/paclitaxelTRTCALGB9801InductionPCNoInduct27SWOG0023PE/TRTConsolidationdocetaxelOralGefitinibplaceboSWOG0023PE/TRTConsolidationdo28ManagementofunresectablestageⅢnon-smallcelllungcancer:theroleofcombinedchemoradiationManagementofunresectablesta29introduction
Untilthelate1980s,thoracicradiationtherapy(TRT)remainedthestandardcareforlocallyadvancedNSCLC.introductionUntilthelate130Radiationalone?Sequentialchemoradiation?Radiationalone?Sequentialch31CALGB8433RT60GyPV2cycles＋RT60GyNo.7779MST9.713.81-yearsurvival40552yearsurvival13263yearsurvival11235yearsurvival719Pvalue0.0066DillmanRO,NEJM323:940-945,1990DillmanRO,JNCI88:1210-1215,1996CALGB8433RT60GyPV2cycles＋RT60G32RTOG8808RT60GyCT+RTH-RT69.6GyNo152152154MST11.413.2121-yearsurvival4759522-yearsurvival2132243-yearsurvival1117145-yearsurvival6119Pvalue
0.04SauseW,JNCI1995;87:198-205SauseW,CHEST2000;117:358-364RTOG8808RT60GyCT+RTH-RT69.6GyN33OSOS34<60ysurvival<60ysurvival35FRANCERT65GyCT+RT65GyP值No177176MST10120.081-yearsurvival41502-yearsurvival14213-yearsurvival511Metastasisrate3826<0.0011-yearLCR1715ThierryLeChevaliar,JNCI1991;83:417-423CT:VCPC,vindesine,cyclophosphamide,cisplatin,lomustineFRANCERT65GyCT+RT65GyP值No1771736Concurrentchemoradiation?Radiationalone?Concurrentchemoradiation?Radi37EORTCRT55PDD(W)+RTPDD(D)+RTNo3113113111-ysurvival4644542-ysurvival1319263-ysurvival21316Pvalue0.0091-yLCR193031Pvalue0.003Schaake-KoningC,NEJM1992;326:524-530EORTCRT55PDD(W)+RTPDD(D)+RTNo338IntensifiedregimenH-RTH-RT/CTH-RT/CTNo615256methods64.8Gy64.8/CE64.8/CEMST818133-ysurvival6.62316JeremicB,JCO1995;13:452-458LeeJS,JCO1994;14:1055-1064CT:weekly,100mg/m2CBPD1,D2;100mg/m2VP-16D1-3CT:200mg/m2CBPD1,D2;100mg/m2VP-16D1-5,thefirst,third,andfifthweeks
IntensifiedregimenH-RTH-RT/CT39MetaAnalysisResults(52trials,9387pts)
2-yearsurvival4%。
Hazard
ratio:0.87。NSCLCCG,BMJ1995;311:899-909MetaAnalysisResults(52trial40Concurrentchemoradiation?Sequentialchemoradiation?Concurrentchemoradiation?Sequ41concurrentsequentialPvalueNo156158methods56Gy/MVP2CMVP2C+56MST16.513.30.042-ysurvival34.627.43-ysurvival22.314.74-ysurvival16.910.15-ysurvival15.88.9ResponseR84660.0002FuruseK,JCO1999;17:2692-2699JapanconcurrentsequentialPvalueNo142RTOG9410sequentialconcurrentconcurrent+HFNo(total)611RT606069.6methodsPV2CPV2CPEMST14.61715.6A-Toxicity304862L-Toxicity141516CurranWJ,PASCO2000;19:484aRTOG9410sequentialconcurrentco43ACR427(phaseⅡ)seqCon(ind/con)Con(con/adi)No(total)276RT636363CTPC2PC2+CONCON+PC2MST12.51116.1Esophogitis(≥3）42028ChoyH,PASCO2002;abstract:1160ACR427(phaseⅡ)seqCon(ind/con)44GLOT9501SEQCONNo(total)212RT66Gy66CTNP3CindCE+CE2Cadi3/4neutropenia
87.8753/4oesophagitis026.1MST13.915.61-ysurvival56562-ysurvival2335PierreF,PASCO2001;abstract:1246GLOT9501SEQCONNo(total)212RT6645MSTOSE-toxicity
S
C
SCSCfuruse13.3
16.5
916(5)423RTOG14.617.1
1221(4)
425GLOT13.915.6
2435(2)317Czech13.220.6
1542(2)428BROCAT14.019.0
--026ACR42713.817.4
3133(2)328MSTOSE-toxicityS46CALGB9431G/PP/PN/PNo.625855RR7467731-ySur6862653-ySur281923MST18.314.817.7DFSMethods:2cyclesinductionfollowedby2cyclesandconcurrentTRT,66GyVokesEE,JCO2002;20:4191-4198CALGB9431G/PP/PN/PNo.625855RR747CALGB9431CALGB943148SWOG9019Patients:
50pts.IIIB
Treatment:PE2cycles/RTPE2cyclesAlbainKS,JCO2002
温馨提示
- 1. 本站所有资源如无特殊说明，都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等，如果需要附件，请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸，网页内容里面会有图纸预览，若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间，仅对用户上传内容的表现方式做保护处理，对用户上传分享的文档内容本身不做任何修改或编辑，并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容，请与我们联系，我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 初中美术教室管理制度
- HTR7在喉鳞状细胞癌患者不良预后中的作用机制与临床意义探究
- 2025年CCS项目在能源结构调整中的经济效益预测报告
- 2025年CCS技术在能源行业应用的经济效益与产业协同发展策略研究报告
- 2025年Z世代消费偏好分析：新消费品牌如何实现品牌差异化传播报告
- 2025年5G商用深化边缘计算行业市场技术壁垒与突破路径研究报告
- 市场营销第五章-工程量清单计价方式
- 中国羽毛球拍行业发展环境、市场运行格局及前景研究报告-智研咨询（2025版）
- 智研咨询发布：2025年中国轮胎联轴器行业市场全景调查及投资前景预测报告
- 基因编辑技术在妇科疾病基因治疗药物开发中的作用-洞察阐释
- 中脉道和系统文化课件
- 大学生爱国教育十讲（中国海洋大学）知到智慧树章节答案
- 高速公路工程投标文件施工组织设计(技术标)
- （正式版）JBT 9229-2024 剪叉式升降工作平台
- 建筑公司组织关系架构图
- 尿动力学检查操作指南2023版
- 麦凯66客户档案管理表格
- 框架六层中学教学楼工程施工方案
- 浅析Zabbix平台在电力企业信息设备监控中的应用
- 螯合树脂资料
- 数学知识树对称PPT课件
评论
0/150
提交评论